medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2013, Number 3

<< Back

Salud Mental 2013; 36 (3)

Consideraciones metodológicas y éticas para la conducción de ensayos clínicos controlados aleatorizados (ECCA) sobre intervenciones para las adicciones

Marín-Navarrete R, Fernández-Mondragón J, Eliosa-Hernández A, Templos NL, Graue-Moreno J, Galván-Sosa D, Fernández-De la Fuente C, Gómez-Valencia G, Berlanga C

Language: Spanish
References: 66
Page: 253-265
PDF size: 202.80 Kb.


ABSTRACT

According to epidemiologic reports, the harmful use of alcohol and illicit drugs has increased among the Mexican population. This use is associated to several risks and issues that affect public health and the public well-being of the country. In this article it is acknowledged the need for development of treatment models and interventions whose therapeutic value is demonstrated by scientific evidence, that respond to the attention needs of the population affected by substance use in our country and that can be generalized in community clinical practice.
In clinical research, randomized controlled clinical trials (RCT’s) are the “gold standard” to demonstrate the effect of a therapeutic intervention. A randomized controlled clinical trial is a prospective study in which the effect, value and safety of one or various experimental interventions are tested against a “control” intervention in human subjects.
Acknowledging that in Mexico there is a lack of research on addiction treatment that is compliant with all the requirements to be considered as an RCT, this article presents some methodological and ethical considerations that are neccesary for their design and conduction. These considerations include from the establishment of a relevant research question and objectives, adequate study design, development of strategies for data management, statistical analysis, monitoring of interventions, safety monitoring and research quality assurance and protection of human subjects.


REFERENCES

  1. UNODC. World Drug Report 2012. United Nations publication. Sales No. E.12.XI.1

  2. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz; Instituto Nacional de Salud Pública; Secretaría de Salud. Encuesta Nacional de Adicciones 2011; México; 2012.

  3. Secretaria de Salud. Subsecretaría de Prevención y Promoción de la Salud. Dirección General Adjunta de Epidemiología. Dirección de Investigación Operativa Epidemiológica. Sistema de Vigilancia Epidemiológica de las Adicciones (SISVEA). Informe 2009; México; 2009.

  4. World Health Organization. The Global Burden of Disease: 2004 update. United Nations publication.; 2008.

  5. Ocampo R., Bojórquez I., Cortés M. Consumo de sustancias y suicidios en México; resultados del Sistema de Vigilancia Epidemiológica de las Adicciones, 1994-2006. Salud Pública Mex; 2009; 51: 306-313.

  6. WHO, UNODC. Principles of Drug Dependence Treatment: Discussion Paper. United Nations publication 2008.

  7. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379:55-70.

  8. Strang J., Babor T., Caulkins, J., Fischer B., Foxcroft D., Humphreys K. Drug policy and the public good: evidence for effective interventions. Lancet 2012; 379: 71-83.

  9. Friedman LM, Furberg CD, DeMets, DL. Fundamentals of Clinical Trials. 4th. Ed. New York. Springer; 2010.

  10. Lazcano-Ponce E, Salazar-Martínez E, Gutierrez-Castrellón P, Angeles- Llerenas A, Hernández-Garduño, A. Viramontes, JL. Ensayos clínicos aleatorizados: variantes, métodos de aleatorización, análisis, consideraciones éticas y regulación. Salud Pública Mex; 2004; 46(6): 559-584.

  11. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Harmonised Tripartite Guideline: General considerations for Clinical Trials. E8. ICH Harminised Tripartite Guideline; 1997. Obtenido en: www.ich.org.

  12. Moher D, Shulz K, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-1991.

  13. McLelland, T. Congratularions on the 10-year anniversary of the National Drug Abuse Treatment Clinical Trial Network – Now, what’s new for the coming decade?. Journal of Substance Abuse Tretment; 2010; 38(Suppl 1): S1-S3.

  14. Rojas E, Real T, García-Silberman S, Medina-Mora ME. Revisión sistemática sobre tratamiento de adicciones en México. Salud Mental 2011; 34: 351-365.

  15. Marín-Navarrete R, Benjet C, Borges G, Eliosa-Hernández A, Nanni- Alvarado R, Ayala-Ledesma, M, Fernández-Mondragón J, Medina- Mora ME. Comorbilidad de los trastornos por consumo de sustancias con otros trastornos psiquiátricos en centros residenciales de ayudamutua para la atención de las adicciones (CRAMAA). En prensa.

  16. Tiet QQ, Mausbach, B. Treatments for patients with dual diagnoses: a review. Alcoholism: Clinical and Experimental Research 2007; 31(4): 513-536.

  17. Medina-Mora ME, Borges G, Lara-Muñoz C, Benjet C, Blanco-Jaimes J, Fleiz-Bautista C, Villatoro-Velázquez J, Rojas-Guiot E, Zambrano- Ruiz J, Casanova-Rodas L, Aguilar-Gaxiola S. Prevalencia de trastornos mentales y uso de servicios: Resultados de la Encuesta Nacional de Epidemiología Psiquiátrica en México. Salud Mental 2003; 26(4):1-16.

  18. Carroll K. Dissemination of evidence-based practices: how far we’ve come, and how much further we’ve got to go; Addiction 2012; 107: 1031-1033.

  19. Lees B, Nitsch D, Wang D, Bakhai A. Patient Selection. En: Wang , Bakhai A (eds). Clinical Trials. A Practical Guide to Design, Analysis, and Reporting. Chicago. Remedica; 2006.

  20. Clarke G. Improving the transition from basic efficacy research to effectiveness research in substance abuse treatment. Journal of Substance Abuse Treatment; 1995; 63(5): 718-725.

  21. Robbins M, Alonso E, Horigian V, Bachrach K, Burlew K, Carrión I, Hodgkins C, Miller M, Schindler E, VanDeMark , Henderson C, Szapocznik J. Transporting Clinical Research to Community Settings: Designing and Conducting a Multisite Trial of Brief Strategic Family Therapy. Addiction Science & Clinical Practice; 2010; 5(2): 54-61.

  22. Hien D, Cohen L, Campbell A. Methodological Innovation to Increase the Utility and Efficiency of Psychotherapy Research for Patients with Co-ocurring Mental Health and Substance Use Disorders. Professional Psychology Research and Practice; 2009; 40(5): 502-509.

  23. Green S. Design of Randomized Trials. Epidemiologic Reviews; 2002; 24(1): 4-11.

  24. Carroll K, Onken L. Behavioral Therapies for Drug Abuse. American Journal of Psychiatry; 2005; 162: 1452-1460.

  25. Onken L, Blaine J, Battjes, R. Behavioral therapy research: A conceptualization of a process. En: Henngler S, Amentos R (eds), Innovative approaches from difficult to treat populations. Rochester, N.Y: University of Rochester Press; 1997.

  26. Rounsaville B, Carroll K, Onken L. A Stage Model of Behavioral Therapies Research: Getting Started and Moving on From Stage 1. Clinical Psychology and Social Practice; 2001; 8:133-142.

  27. Knatterud GL. Management and Conduct of Randomized Controlled Trials. Epidemiologic Reviews; 2002; 24(1): 12-25.

  28. European Medicines Agency (2006) Statistical Principles for Clinical Trials. Recuperado de http://www.emea.eu.int

  29. Guillén A., Carreño A., Canal N. (2006) Fases del análisis estadístico de los datos de un estudio. En Guillén A y Crespo R. (Ed.) Métodos estadísticos para enfermería nefrológica. (pp. 247-260) España: Sociedad Española de Enfermería Nefrológica, SEDEN. Recuperado de http:// www.revistaseden.org/files/17-CAP 17.pdf

  30. Lazcano-Ponce E., Salazar-Martínez E., Gutiérrez-Castrellón P., Ángeles- Llerenas A., Hernández-Garduño A., Viramontes J.L. (2009). Ensayos Clínicos Aleatorizados. En Hernández M. (Ed.). Epidemiología: Diseño y análisis de estudios. (1ª ed., pp.77-119). México: Editorial Médica Panamericana e Instituto Nacional de Salud Pública.

  31. Álvarez-Cáceres R. (2005). Ensayos Clínicos: diseño, análisis e interpretación. España: Díaz de Santos.

  32. Peduzzi P., Henderson W., Hartigan P., Lavori P. (2002). Analysis of Randomized Controlled Trials. Epidemiol Rev, 1(24), 26-38.

  33. Cramer J, Roy A. Burrell A, Fairchild C, Fuldeore M, Ollendorf D, Wong P. Medication Compliance and Persistence: Terminology and Definitions. Value in Health; 2008. 11(1): 44-47.

  34. Farmer K. Methods for measuring and monitoring medication adherence in clinical trials and clinical practice. Clinical Therapeutics; 1999; 21(6): 1074-1090.

  35. Kazdin AE. Methods of psychotherapy research. En Bongar B, Beutler E (eds.). Comprehensive textbook of psychotherapy: Theory and practice. New York: Oxford University Press.

  36. Yeaton, W. H. & Sechrest, L. (1981). Critical dimensions in the choice and maintenance of successful treatments: Strength, integrity, and effectiveness.(Journal of Consulting and Clinical Psychology, 49, 156- 167).

  37. Carroll K, Martino S, Rousanville B. No Train, No Gain? Clinical Psychology: Science and Practice 2010;17:36-40.

  38. Waskow IE. Specification of the technique variable in the NIMH Treatment of Depression Collaborative Research Program. En Williams J, Spitzer R (eds). Psychotherapy research: Where are we and where should we go. New York: Guilford Press;1984.

  39. Chambless DL, Hollon SD. Defining empirically supported therapies. Journal of Consulting and Clinical Psychology 1998;66:7–18.

  40. Beidas R, Kendall PC. Training therapists in evidence-based practice: A critical review of studies from a systems-contextual perspective. Clinical Psychology: Science and Practice 2010;17: 1–30.

  41. Marcus M, Liehr P, Schmitz J, Moeller G, Swank P, Fine M, Cron S, Granmayeh K, Carroll D. Behavioral Therapies Trials: A Case Example. Nurs Res 2007;56(3):210–216.

  42. Carroll K, Farentinos C, Ball S, Crits-Christoph P, Libby B, Morgenstern J, Obert J, Polcin D, Woody G. MET meets the real world: design issues and clinical strategies in the Clinical Trials Network. Journal of Substance Abuse Treatment 2002;23:73–80.

  43. Miller W, Yahne C, Moyers T, Martínez J, Pirritano M. A Randomized Trial of Methods to Help Clinicians Learn Motivational Interviewing. Journal of Consulting and Clinical Psychology 2004;72:1050–1062.

  44. Martino S, Carroll K, Ball S. Teaching, monitoring and evaluating motivational interviewing practice. En Tober G, Raistrick D. (eds). Motivational Dialogue: preparing addiction professionals for motivational interviewing practice. New York: Routledge/Taylor & Francis Group; 2007.

  45. Carpenter KM, Cheng WY, Smith JL, Brooks AC, Amrhein PC, Wain RM, Nunes EV. “Old dogs” and new skills: how clinician characteristics relate to motivational interviewing skills before, during, and after training. J Consult Clin Psychol. 2012;80(4):560-573.

  46. Martino S, Ball S, Nich C, Canning-Ball M, Rounsaville B, Carroll K. Teaching community program clinicians motivational interviewing using expert and train-the-trainer strategies. Addiction 2010;106:428–441.

  47. Amodeo M, Storti S, Larson, M. Moving Empirically Supported Practices to Addiction Treatment Programs: Recruiting Supervisors to Help in Technology Transfer. Substance Use and Misuse 2010;45:968–982.

  48. O´Donovan A, Halford W, Walters B. Towards Best Practice Supervision of Clinical Psychology Trainees. Australian Psychologist 2011;46:101–112.

  49. Sugarman J. Ethics in the Design and Conduct of Clinical Trials. Epidemiologic Reviews; 2002; 24(1): 54-58.

  50. Adrian M, Barry S. Physical and mental health problems associated with the use of alcohol and drugs. Substance Use and Misuse; 2003; 38: 1575-15614.

  51. Petry N. Roll J, Runsaville B, Ball S, Stitzer M, Peirce, J, Blaine J, Kirby K, McCarty D, Carroll K. Serious adverse events in randomized psychosocial treatment studies: Safety of Arbitrary Edicts? J Consult Clin Psycol; 2008; 76(6):1076-1082.

  52. Horigian V, Robbins M, Dominguez R, Ucha J, Rosa C. Principles for defining adverse events in behavioral intervention research: lessons from a family-focused adolescent drug abuse trial. Clinical Trials; 2010; 7(1): 58-68.

  53. McFadden E. Management of Data in Clinical Trials. 2nd. Ed. Hoboken N.J. Wiley Series in Probability and Statistics; 2007.

  54. Krishnankutty B, Bellary S, Kumar B, Moodahahu L. Data management in clinical research. Educational Forum; 2012; 44(2): 168-172.

  55. Freedman B. Equipoise and the ethics of clinical research. New England Journal of Medicine; 1987; 317(3): 141-154.

  56. Ubel P, Silbergleit R. Behavioral equipoise: a way to resolve ethical stalemates in clinical research. The American Journal of Bioethics; 2011; 11(2): 1-8.

  57. Weijer C, Shapiro S, Cranley-Glass K, Enkin M. For and Against: Clinical Equipoise and not the uncertainty principle is the moral underpinning of the randomized controlled trial. British Medical Journal; 2000; 321: 756-758.

  58. Tribunal Internacional de Núremberg. Código de Núremberg. 1947. Obtenido de: www.bioeticanet.info/documentos/Nuremberg.pdf

  59. World Medical Association; WMA Declaration of Geneva. 1948. Obtenido de: http://www.wma.net/en/30publications/10policies/g1/

  60. Declaración de Helsinki de la Asociación Médica Internacional. Principios éticos para las investigaciones médicas en seres humanos. Seúl; Asamblea Médica Internacional; 2008. Obtenido en: www.wma.net/ es/30publications/10policies/b3/17c_es.pdf

  61. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. El Informe Belmont. Principios y Guías éticas para la protección de los sujetos humanos en investigación. EE.UU., 1979. Obtenido en www.bioeticaweb.com/index2. php?option_content&do_pdf=1&id=1060.

  62. Reglamento de la Ley General de Salud en materia de Investigacion para la Salud. Título Segundo: de los aspectos éticos de la investigación en seres humanos. Capítulo 1: Disposiciones generales. 1983. Obtenido en: http://www.salud.gob.mx/unidades/cdi/nom/compi/rlgsmis.html

  63. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. E6(R1.; 1996. Obtenido en: www.ich.org.

  64. Organización Panamericana de la Salud. Grupo de trabajo en Buenas Prácticas Clínicas. Buenas Prácticas Clínicas: Documento de las Américas. Obtenido en www.paho.org/spanish/ad/ths/ev/BPC-doct-esp.doc

  65. Mondragón-Barrios L. Ética en la Investigación Psicosocial. Salud Mental; 2007; 30(6): 25-31

  66. Chan A-W, Tetzla JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013; 158 (en prensa).




2020     |     www.medigraphic.com